PYRIMIDINONES AS FACTOR XIA INHIBITORS

The present invention provides a compound which is (9R,13S)-13-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one trifluoroacetate, or a stereoisomer or ta...

Full description

Saved in:
Bibliographic Details
Main Authors ZHU, Yeheng, ORWAT, Michael J, PABBISETTY, Kumar Balashanmuga, CORTE, James R, YANG, Wu, SMITH II, Leon M, DILGER, Andrew K, WANG, Yufeng, PINTO, Donald J.P, FANG, Tianan, DE LUCCA, Indawati, EWING, William R, WEXLER, Ruth R
Format Patent
LanguageEnglish
French
German
Published 09.11.2016
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The present invention provides a compound which is (9R,13S)-13-{4-[5-chloro-2-(4-chloro-1H-1,2,3-triazol-1-yl)phenyl]-6-oxo-1,6-dihydropyrimidin-1-yl}-3-(difluoromethyl)-9-methyl-3,4,7,15-tetraazatricyclo[12.3.1.02,6]octadeca-1(18),2(6),4,14,16-pentaen-8-one trifluoroacetate, or a stereoisomer or tautomer thereof. This invention also relates to pharmaceutical compositions comprising this compound and their use in the treatment of thromboembolic disorders.
Bibliography:Application Number: EP20150747721